Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust

Postepy Dermatologii i Alergologii

Volumn 31, Issue 1, 2014, Pages 39-44

  Kupryś Lipińska, Izabela ^a   Korczynśka, Paulina ^a   Tworek, Damian ^a   Kuna, Piotr ^a  

^a Department of Internal Medicine Asthma and Allergy Norbert Barlicki Memorial University Hospital No 1 Medical University of Lodz ^*  (Poland)

Author keywords

Chronic urticaria; Life threatening angioedema; Omalizumab; Severe asthma

Indexed keywords

FLUTICASONE; FORMOTEROL; IMMUNOGLOBULIN E; MONTELUKAST; OMALIZUMAB; POLLEN ANTIGEN; PREDNISOLONE; VACCINE;

ADULT; ALLERGIC ASTHMA; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CASE REPORT; CHRONIC URTICARIA; DISEASE EXACERBATION; DRUG EFFICACY; DUST EXPOSURE; FEMALE; HOUSE DUST; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; LARYNX EDEMA; MEDICAL HISTORY; QUALITY OF LIFE; REMISSION; STEROID THERAPY; VIRAL RESPIRATORY TRACT INFECTION;

EID: 84896768026     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2014.40659     Document Type: Article

References (31)

1. Kuprý-Lipińska I, Kuna P. Omalizumab, recombinant humanized monoclonal antibody anti-IgE: new fields of studies on the therapeutic indications. Pneumonol Alergol Pol 2009; 77: 43-51.
2. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16. (Pubitemid 40293346)
3. Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013; 17: 1-342.
4. Walker S, Burch J, McKenna C, et al. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. Health Technol Assess 2011; 15 Suppl. 1: 13-21.
5. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; 2: CD003559.
6. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-8. (Pubitemid 40293345)
7. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102: 71-6. (Pubitemid 350161845)
8. Barnes N, Menzies-Gow A, Mansur AH, et al. Efectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma 2013; 50: 529-36.
9. Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42: 1224-33.
10. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117: 1415-8. (Pubitemid 43795744)
11. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007; 120: 979-81. (Pubitemid 47534214)
12. Máspero JF, Parisi CA, De Gennaro M, et al. Chronic autoimmune urticaria: treatment with omalizumab. Arch Argent Pediatr 2009; 107: 452-6.
13. Korkmaz H, Eigelshoven S, Homey B. Omalizumab for therapy-resistant chronic urticaria with angioedema. Hautarzt 2010; 61: 828-31.
14. Sánchez-Machín I, Iglesias-Souto J, Franco A, et al. T cell activity in successful treatment of chronic urticaria with omalizumab. Clin Mol Allergy 2011; 9: 11.
15. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 247-9.
16. Güzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 1563-5.
17. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010; 65: 138-9.
18. Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Efective treatment of refractory severe heat urticaria with omalizumab. Allergy 2010; 65: 931-2.
19. Krause K, Ardelean E, Kessler B, et al. Antihistamine-resistant urticariafactitia successfully treated with anti-immunoglobulin E therapy. Allergy 2010; 65: 1494-5.
20. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010; 90: 443-4.
21. Máspero JF, Parisi CA, De Gennaro M, et al. Chronic autoimmune urticaria: treatment with omalizumab. Arch Argent Pediatr 2009; 107: 452-6.
22. Al-Ahmad M. Omalizumab therapy in three patients with chronic autoimmune urticaria. Ann Saudi Med 2010; 30: 478-81.
23. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128: 202-9.
24. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567-73.
25. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-35.
26. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569-73.
27. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticarial. Allergy 2009; 64: 1417-26.
28. Kołacińska-Flont M, Antczak-Marczak M, Pawłowski M, Kuna P. Anti-Helicobacter pylori IgG titre in patients with chronic idiopathic urticaria and the efect of Helicobacter pylori eradication on urticarial. Postep Derm Alergol 2012; 29: 8085.
29. Ucmak D, Akkurt M, Toprak G, et al. Determination of dermatology life quality index, and serum C-reactive protein and plasma interleukin-6 levels in patients with chronic urticarial. Postep Derm Alergol 2013; 30: 146-51.
30. Gomułka K. Cold urticaria: a case report. Postep Derm Alergol 2012; 29: 60-2.
31. Brzeski PŁ, Spałkowska M, Podbielska M, et al. The role of focal infections in the pathogenesis of psoriasis and chronic urticaria. Postep Derm Alergol 2013; 30: 77-84.